Russell Finex boosts API microsphere sieving efficiency
A global pharmaceutical manufacturer producing high-value sterile active pharmaceutical ingredients (APIs), including peptide-based medicines A leading pharmaceutical manufacturer produces over 250 high-value sterile active pharmaceutical ingredients (APIs), including complex peptide formulations such as Octreotide. These APIs form the critical components within medicines, delivering essential therapeutic benefits.
Using aseptic manufacturing processes, the company produces microsphere powders, tiny, spherical particles ranging from 1 to 1,000 microns. These particles are central to advanced drug delivery systems, requiring precise and hygienic handling throughout production.
Following initial processing, the manufacturer sieves the microsphere powders at 71 microns using an ultrasonic sifter within a sterile, controlled environment. However, the existing solution posed significant challenges. With a limited throughput of just 1.5 kg/hour, the system could not meet increasing market demand, restricting production scalability.
To overcome these limitations, the manufacturer explored alternative GMP-compliant…
